VIVUS Announces New Qsymia Offer

                       VIVUS Announces New Qsymia Offer


PR Newswire

MOUNTAIN VIEW, Calif., March 5, 2013

MOUNTAIN VIEW, Calif., March 5, 2013 /PRNewswire/ --VIVUS, Inc. (Nasdaq:
VVUS) today announced a new program offering eligible patients a discount on
Qsymia^® (phentermine and topiramate extended-release) capsules CIV for a
limited time. The Save Now! Program is available online exclusively at and provides patients with the opportunity to pay no more than
$75 for 30 days of the recommended dose (Qsymia 7.5 mg/46 mg). This
represents up to $85 savings off the full retail price (which may vary by
pharmacy) for this once daily therapy.

"We believe our Qsymia offer programs provide more patients struggling with
obesity the opportunity to partner with their physicians to experience the
benefits of Qsymia," said Peter Y. Tam, president of VIVUS. "Our goal is to
take every measure to make Qsymia more accessible to patients today as we
continue to make progress toward achieving reimbursement for patients who

Qsymia is the only FDA-approved once daily combination therapy – and the first
medication available in 13 years – for chronic weight management.

To obtain the offer, patients must have a valid prescription issued by a
physician. The offer is limited to one per patient for the duration of the
program. Patients who qualify for the offer program are eligible to receive
30 days of the recommended dose (7.5 mg/46 mg) of Qsymia once daily for no
more than $75.

It is suggested that new patients initiate therapy on the Qsymia starting dose
of 3.75 mg/23 mg for 14 days and then increase to the Qsymia recommended dose
of 7.5 mg/46 mg. This new offer complements the Qsymia Get Started! Free Trial
Program, which provides eligible patients a free trial on a valid prescription
for up to 14 capsules of the Qsymia starting dose (3.75 mg/23 mg). For more
information, visit

* Based on the full retail price of 30 capsules of Qsymia 7.5 mg/46 mg ($85
savings), and the full retail price of 14 capsules of the Qsymia starting
dose, 3.75 mg/23 mg ($65 savings), for a total of $150.

About Qsymia
Qsymia is approved in the U.S. and is indicated as an adjunct to a
reduced-calorie diet and increased physical activity for chronic weight
management in adults with an initial body mass index (BMI) of 30 kg/m^2 or
greater (obese) or 27 kg/m^2 or greater (overweight) in the presence of at
least one weight-related medical condition such as high blood pressure, type 2
diabetes, or high cholesterol.

The effect of Qsymia on cardiovascular morbidity and mortality has not been
established. The safety and effectiveness of Qsymia in combination with other
products intended for weight loss, including prescription and over-the-counter
drugs, and herbal preparations, have not been established.

Important Safety Information
Qsymia (phentermine and topiramate extended-release) capsules CIV is
contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism;
in patients receiving treatment or within 14 days following treatment with
monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to
sympathomimetic amines, topiramate, or any of the inactive ingredients in

Qsymia can cause fetal harm. Females of reproductive potential should have a
negative pregnancy test before treatment and monthly thereafter and use
effective contraception consistently during Qsymia therapy. If a patient
becomes pregnant while taking Qsymia, treatment should be discontinued
immediately, and the patient should be informed of the potential hazard to the

The most commonly observed side effects in controlled clinical studies, 5% or
greater and at least 1.5 times placebo, include paraesthesia, dizziness,
dysgeusia, insomnia, constipation, and dry mouth.

About Qsymia Offer Programs
Save Now! Program - Eligible patients for the Save Now! Program must reside in
one of the 50 states and Washington, DC, Puerto Rico, Virgin Islands, or Guam,
and be 18 years or older. This offer is limited to one per patient and
applies only to the Qsymia recommended dose of 7.5 mg/46 mg for 30 days. This
offer is available for a limited time and may be modified or discontinued
without further notice. Prescriptions written or filled prior to March 1,
2013 are not eligible for the Save Now! Program. This offer is not

This program is not open to patients receiving prescription reimbursement for
Qsymia under any federal, state, or government-funded insurance program (for
example, Medicaid, Tricare, VA, Department of Defense, Indian Health Service)
or where prohibited by law. Qsymia is categorically excluded from Medicare
coverage. Therefore, if you have Medicare coverage, including under Medicare
Part D, and no other additional federal or state healthcare program coverage,
you are eligible for this program.

Prescriptions for Qsymia and the Save Now! Program are redeemable by mail
order only through CVS/pharmacy, Walgreens, and Walmart Home Delivery
Pharmacy. Qsymia is not available at your local retail pharmacy. Patients
are responsible for any sales tax. You may not submit a claim for the amounts
covered by the offer for payment to any third-party payers, including a
flexible spending account, a Health Savings Account (HSA), or a Health
Reimbursement Account (HRA).

Acceptance of this offer must be consistent with the terms of any drug benefit
provided by your health insurer, health plan, or private third-party payer,
and you agree to report acceptance of this offer to your health insurer,
health plan, or third-party payer as may be required.

Get Started! Program - Eligible patients for the Get Started! Program must
reside in one of the 50 states, Puerto Rico, Virgin Islands, or Guam, and be
18 years or older. This offer is limited to one per patient, and applies only
to the Qsymia starting dose of 3.75mg/23mg for 14 days. This offer is
available for a limited time and may be modified or discontinued without
further notice. Prescriptions written or filled prior to November 16, 2012,
are not eligible for the free trial program.

This offer is good for the purchase of Qsymia only through CVS/pharmacy,
Walgreens, and Walmart Home Delivery Pharmacy mail order pharmacies in the
Qsymia Home Delivery Network and lawfully purchased from an authorized
pharmacy in the United States or its territories. This offer is not insurance
and is not valid for prescriptions purchased under Medicaid, Medicare, or
similar federal or state programs or for patients who are Medicare eligible
and enrolled in an employer-sponsored group waiver health plan or
government-subsidized prescription drug benefit program for retirees. Offer
not valid where prohibited by law, taxed, or restricted. Offer is not
transferable, is limited to one free trial offer per person, and may not be
combined with any other offer. A valid prescription for Qsymia is required at
the time of purchase.

VIVUS is a biopharmaceutical company commercializing and developing
innovative, next-generation therapies to address unmet needs in obesity, sleep
apnea, diabetes and sexual health for U.S., Europe and other world markets.
Qsymia is also in phase 2 clinical development for the treatment of type 2
diabetes and obstructive sleep apnea. For more information about the company,
please visit

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely,"
"may," "plan," "potential," "predict," "opportunity" and "should," among
others. There are a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements. These
factors include, but are not limited to, our limited commercial experience
with Qsymia in the U.S.; the timing of initiation and completion of the
clinical studies required as part of the approval of Qsymia by the United
States Food and Drug Administration, or FDA; the response from the FDA to the
data that VIVUS will submit relating to post-approval clinical studies; the
impact of the indicated uses and contraindications contained in the Qsymia
label and the Risk Evaluation and Mitigation Strategy, or REMS, requirements;
the impact of distribution of Qsymia through a certified home delivery
pharmacy network; whether or not the FDA approves our amendment to the REMS
for Qsymia, which, if approved, would allow dispensing through select
certified retail pharmacies to increase access while meeting all requirements
of the REMS; that we may be required to provide further analysis of previously
submitted clinical trial data; the negative opinion of the European Medicines
Agency's, or EMA, Committee for Medicinal Products for Human Use, or CHMP, for
the Marketing Authorization Application, or MAA, for Qsymia; our ability to
successfully commercialize or establish a marketing partnership for avanafil,
which will be marketed in the U.S. under the name STENDRA™; the ability of our
partners to obtain and maintain regulatory approvals to manufacture and
adequately supply our products to meet demand; our history of losses and
variable quarterly results; substantial competition; risks related to the
failure to protect our intellectual property and litigation in which we may
become involved; uncertainties of government or third party payer
reimbursement; our reliance on sole source suppliers; our limited sales and
marketing and manufacturing experience; our reliance on third parties and our
collaborative partners; our failure to continue to develop innovative
investigational drug candidates and drugs; risks related to the failure to
obtain FDA or foreign authority clearances or approvals and noncompliance with
FDA or foreign authority regulations; our ability to demonstrate through
clinical testing the safety and effectiveness of our investigational drug
candidates; the timing of initiation and completion of clinical trials and
submissions to foreign authorities; the results of post-marketing studies are
not favorable; compliance with post-marketing regulatory standards is not
maintained; the volatility and liquidity of the financial markets; our
liquidity and capital resources; and our expected future revenues, operations
and expenditures. As with any pharmaceutical in development, there are
significant risks in the development, the regulatory approval, and the
commercialization of new products. There are no guarantees that the product
will receive regulatory approval outside the United States for any indication
or prove to be commercially successful. VIVUS does not undertake an obligation
to update or revise any forward-looking statements. Investors should read the
risk factors set forth in VIVUS's Form 10-K for the year ending December 31,
2012, and periodic reports filed with the Securities and Exchange Commission.


Contact: Timothy E. Morris, Chief Financial Officer of VIVUS, Inc.,; Media Relations: Ashley Buford of GolinHarris,
+1-212-373-6045,; Investor Relations: Brian Korb of
The Trout Group, +1-646-378-2923,
Press spacebar to pause and continue. Press esc to stop.